



Sample content

Ulcerative Colitis

China In-Depth



Sample content

China In-Depth provides comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Methodology and scope

Market forecast

- **Forecast:** 10-year, annualized, drug-level sales and patient shares of key ulcerative colitis therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
- **Epidemiology:** Total diagnosed prevalent cases of UC in both urban and rural China. Clinically and market relevant drug-treatable populations.
- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Qualitative and quantitative insights driven by 5 interviews with thought-leading gastroenterologists in China and surveys of 50 gastroenterologists China.
- Supported by survey data collected for this and other Clarivate research.

Geography



China

Coverage

- Key therapies included in the analysis:

Phase 3	Marketed
• Ozanimod (BMS)	• Remicade (JNJ)
• Ivarmacitinib (Jiangsu Hengrui)	• Entyvio (Takeda)
• ABX464 (Abivax)	• Rinvoq (AbbVie)
• Mirikizumab (Eli Lilly)	

Primary market research methodology


- **Ulcerative Colitis | China In-Depth** is a primary market research study evaluating physician self-reported prescribing and treatment practices for UC.
- We interviewed five gastroenterologists in China.
 - The interviews were conducted from March to April 2024.
 - Each interview was conducted over the phone and lasted approximately 45 minutes.
 - All experts we interviewed have active medical practices with a specific interest in gastric disorders.
- E-mail invitations were sent to gastroenterologists to participate in a 30-minute online survey.
- 50 gastroenterologists completed the survey.
- Surveys were programmed in the local language.
- Fieldwork occurred from March to April 2024.
- To qualify, respondents met the following screening criteria:
 - Specialists in UC treatment.
 - Manage at least 10 UC patients.
 - Prescribe at least aminosalicylates, corticosteroids, immunosuppressants, infliximab (J&J's Remicade, biosimilars), vedolizumab (Takeda's Entyvio), and upadacitinib (AbbVie's Rinvoq) outside of clinical trials in 2023.
 - Be in practice for a minimum of 5 years and a maximum of 35 years.
 - Practice in a tier II or III general hospital.
 - Devote more than 50% of their professional time to direct patient care.
- After meeting the screening criteria, respondents were directed to an online survey and were paid an honorarium for their participation.

Sample content

Question answered

What are the expected sales of key drugs classes used to treat ulcerative colitis in the China over the next 10 years?

Sales of key drug classes for ulcerative colitis in China: 2023-2033




Sample content

Question answered

What are the expected sales of ulcerative colitis emerging therapies in China over the next 10 years?

Sales of emerging therapies for ulcerative colitis in China: 2023-2033




Sample content

Question answered

What is the current treatment paradigm in ulcerative colitis?

Treatment algorithm: ulcerative colitis




Sample content

Question answered

What are the factors influencing physician's treatment decision in clinical practice for ulcerative colitis?

Factors influencing physicians' treatment decisions in clinical practice




Sample content

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?

Unmet needs in ulcerative colitis




Sample content

Question answered

Who will be the leading key players in ulcerative colitis market in 2333?

Leading players for ulcerative colitis in 2033





Contact our experts today:
healthcare.support@clarivate.com
clarivate.com

About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

© 2024 Clarivate

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.